Hospital
Nebraska Methodist Hospital
Nebraska Methodist Hospital was paid $14.47M by Medicaid between Jan 2018 and Dec 2024, across 277 billing codes. Its largest line is 99284, emergency room visit (serious) — 9.9% of everything it billed.
33Billing provider infoNEBRASKA METHODIST HOSPITAL
OMAHA, NE 68114
OMAHA, NE 68114
33aNPI1427147883assigned 10/12/2006
33bProvider typeWomen's Hospital
28Total paid$14.47M
24GClaims573,658
24DCodes billed277
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 69,785 | $1.87M | |
| 2019 | 69,873 | $1.83M | |
| 2020 | 69,608 | $1.85M | |
| 2021 | 135,144 | $3.05M | |
| 2022 | 145,663 | $3.21M | |
| 2023 | 61,872 | $1.66M | |
| 2024incomplete | 21,713 | $996K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.9% | 13,153 | 12,243 | $1.44M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.4% | 5,894 | 4,287 | $1.35M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.1% | 12,193 | 11,356 | $1.31M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.6% | 2,998 | 2,831 | $949K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.5% | 4,289 | 3,159 | $644K |
| 59025 | Fetal non-stress test | 3.2% | 2,930 | 2,246 | $460K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 2,177 | 2,041 | $443K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 2.8% | 4,952 | 4,402 | $411K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 2.7% | 4,919 | 3,079 | $397K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.7% | 3,901 | 3,589 | $384K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.3% | 8,962 | 8,508 | $327K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 938 | 899 | $284K |
265 more codes
| 80053 | Comprehensive metabolic panel | 1.8% | 46,272 | $266K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 3,145 | $255K |
| 76819 | Fetal biophysical profile; without non-stress testing | 1.7% | 4,898 | $244K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 1,374 | $237K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.5% | 13,576 | $219K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.5% | 8,954 | $217K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.3% | 908 | $188K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 16,609 | $184K |
| G0378 | Hospital observation service, per hour | 1.1% | 2,758 | $161K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.0% | 761 | $150K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.0% | 544 | $147K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,740 | $144K |
| 58661 | <1% | 27 | $119K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,092 | $114K |
| 84439 | <1% | 9,405 | $114K | |
| J3490 | Unclassified drugs | <1% | 26,909 | $99K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,814 | $99K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,988 | $91K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,140 | $88K |
| 80061 | Lipid panel | <1% | 13,449 | $86K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,968 | $82K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,059 | $78K |
| 88142 | <1% | 3,535 | $75K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,929 | $73K |
| 36591 | <1% | 2,144 | $72K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,661 | $68K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,077 | $67K |
| 80055 | <1% | 2,586 | $67K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 29,507 | $66K |
| 87631 | <1% | 568 | $66K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,014 | $62K |
| 84702 | <1% | 4,628 | $60K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,565 | $60K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,705 | $59K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,433 | $58K |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 1,819 | $56K |
| 76820 | <1% | 1,153 | $55K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,672 | $53K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 96 | $53K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,555 | $51K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,161 | $50K |
| 87653 | <1% | 1,274 | $49K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,808 | $48K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,560 | $47K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 257 | $47K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,413 | $46K |
| 93971 | <1% | 350 | $41K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 104 | $37K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 703 | $36K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 512 | $34K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,054 | $34K |
| 80050 | General health panel | <1% | 2,215 | $33K |
| 86141 | <1% | 4,320 | $32K | |
| 86803 | <1% | 3,180 | $32K | |
| 96376 | <1% | 3,295 | $31K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,898 | $30K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,154 | $28K |
| 71250 | <1% | 323 | $27K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 91 | $25K |
| 86703 | <1% | 1,871 | $24K | |
| 82607 | <1% | 2,095 | $24K | |
| 83880 | <1% | 1,758 | $23K | |
| 86769 | <1% | 622 | $23K | |
| 76801 | <1% | 270 | $23K | |
| 87081 | <1% | 2,977 | $23K | |
| 87077 | <1% | 3,587 | $21K | |
| 86900 | <1% | 2,093 | $18K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 2,604 | $17K |
| 82728 | <1% | 1,706 | $17K | |
| 76642 | <1% | 107 | $16K | |
| 83550 | <1% | 2,538 | $16K | |
| 97161 | <1% | 404 | $16K | |
| 88307 | <1% | 331 | $15K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 893 | $15K |
| 76830 | Ultrasound, transvaginal | <1% | 381 | $15K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,384 | $15K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 93 | $14K |
| 87186 | <1% | 3,309 | $14K | |
| 93976 | <1% | 208 | $14K | |
| 84144 | <1% | 788 | $14K | |
| 76821 | <1% | 253 | $13K | |
| 86780 | <1% | 1,159 | $13K | |
| 83655 | <1% | 747 | $12K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,366 | $12K |
| 84703 | <1% | 1,941 | $12K | |
| 83540 | <1% | 2,635 | $12K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 440 | $11K |
| 86850 | <1% | 1,152 | $11K | |
| 70491 | <1% | 41 | $11K | |
| 84484 | <1% | 4,092 | $10K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 32,375 | $10K |
| 83690 | <1% | 4,298 | $10K | |
| 84145 | <1% | 1,745 | $9K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 335 | $9K |
| 83735 | <1% | 3,284 | $8K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 52 | $8K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,716 | $8K |
| 84481 | <1% | 1,000 | $8K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 55 | $7K |
| 84153 | <1% | 664 | $7K | |
| 82570 | <1% | 1,723 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,003 | $7K |
| 85027 | <1% | 2,920 | $7K | |
| 81001 | <1% | 6,483 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,549 | $7K |
| 82746 | <1% | 786 | $6K | |
| 82962 | <1% | 5,784 | $6K | |
| 88304 | <1% | 499 | $6K | |
| 87634 | <1% | 857 | $6K | |
| 80074 | <1% | 485 | $6K | |
| 85007 | <1% | 2,739 | $6K | |
| 77336 | <1% | 46 | $6K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 303 | $5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 304 | $5K |
| 85379 | <1% | 1,718 | $5K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 79 | $5K |
| 97597 | <1% | 24 | $5K | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 35 | $5K |
| 84156 | <1% | 1,751 | $5K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 86 | $5K |
| 86038 | <1% | 432 | $5K | |
| 87205 | <1% | 1,669 | $5K | |
| 99156 | <1% | 1,470 | $4K | |
| 84146 | <1% | 350 | $4K | |
| 87088 | <1% | 614 | $4K | |
| 83605 | <1% | 1,884 | $4K | |
| 85610 | <1% | 2,691 | $4K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 407 | $4K |
| 82565 | <1% | 1,515 | $4K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 409 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,871 | $4K |
| 86901 | <1% | 2,022 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,747 | $4K |
| 87040 | <1% | 1,000 | $4K | |
| 87147 | <1% | 624 | $3K | |
| 81003 | <1% | 4,216 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,290 | $3K |
| 82247 | <1% | 532 | $3K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 15 | $3K |
| 82784 | <1% | 358 | $3K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,501 | $3K |
| 90715 | <1% | 118 | $3K | |
| 82533 | <1% | 218 | $3K | |
| 87070 | <1% | 605 | $3K | |
| 96367 | <1% | 129 | $3K | |
| 83615 | <1% | 977 | $3K | |
| 85651 | <1% | 700 | $2K | |
| 82105 | <1% | 198 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,457 | $2K |
| 83001 | <1% | 202 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 272 | $2K |
| A4217 | Sterile water/saline, 500 ml | <1% | 2,402 | $2K |
| 82465 | <1% | 388 | $2K | |
| 80081 | <1% | 192 | $2K | |
| 85730 | <1% | 1,197 | $2K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 5,145 | $2K |
| 86787 | <1% | 193 | $2K | |
| 87340 | <1% | 283 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,314 | $2K |
| 74018 | <1% | 48 | $2K | |
| 93970 | <1% | 12 | $2K | |
| 82670 | <1% | 116 | $2K | |
| 84403 | <1% | 167 | $2K | |
| 80076 | <1% | 214 | $1K | |
| 88342 | <1% | 194 | $1K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 12 | $1K |
| 76813 | <1% | 25 | $1K | |
| 97165 | <1% | 25 | $1K | |
| 71271 | <1% | 14 | $1K | |
| 82378 | <1% | 115 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 79 | $1K |
| 83516 | <1% | 92 | $1K | |
| 86376 | <1% | 102 | $961.90 | |
| 88341 | <1% | 29 | $954.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 64 | $937.36 |
| 86431 | <1% | 141 | $860.19 | |
| 76000 | <1% | 13 | $807.42 | |
| 97116 | <1% | 41 | $778.15 | |
| 94799 | <1% | 342 | $771.76 | |
| 73630 | <1% | 28 | $722.32 | |
| 87529 | <1% | 27 | $712.66 | |
| 77065 | Tomosynthesis, mammo | <1% | 14 | $705.96 |
| 82550 | <1% | 200 | $645.21 | |
| 86592 | <1% | 61 | $636.23 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 542 | $622.71 |
| 99157 | <1% | 765 | $547.33 | |
| 82950 | <1% | 93 | $539.60 | |
| 82150 | <1% | 109 | $499.46 | |
| 73610 | <1% | 39 | $490.89 | |
| 82248 | <1% | 116 | $488.04 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 323 | $460.03 |
| 84100 | <1% | 287 | $452.60 | |
| 81025 | <1% | 3,399 | $418.61 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,412 | $395.94 |
| 84550 | <1% | 109 | $383.19 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 69 | $374.42 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 40 | $317.04 |
| 73562 | <1% | 56 | $271.25 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 366 | $266.77 |
| 86762 | <1% | 43 | $258.44 | |
| 83970 | <1% | 14 | $249.05 | |
| 83002 | <1% | 25 | $220.23 | |
| 86800 | <1% | 25 | $219.72 | |
| 80143 | <1% | 428 | $216.67 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 97 | $204.10 |
| 94760 | <1% | 882 | $200.76 | |
| 80179 | <1% | 402 | $192.24 | |
| 83525 | <1% | 13 | $184.40 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 321 | $177.84 |
| 73030 | <1% | 28 | $167.01 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 695 | $159.75 |
| 84681 | <1% | 13 | $143.52 | |
| 84270 | <1% | 17 | $143.31 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 314 | $137.46 |
| 82947 | <1% | 27 | $132.55 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 134 | $132.16 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 560 | $127.44 |
| 87210 | <1% | 99 | $122.56 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 147 | $117.27 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,184 | $103.39 |
| 80069 | <1% | 13 | $99.55 | |
| 85018 | <1% | 47 | $91.28 | |
| 80177 | <1% | 14 | $87.45 | |
| 82043 | <1% | 21 | $74.67 | |
| J1815 | Injection, insulin, per 5 units | <1% | 715 | $73.49 |
| 88302 | <1% | 107 | $71.36 | |
| 73502 | <1% | 15 | $66.96 | |
| 86364 | <1% | 12 | $58.10 | |
| 86304 | <1% | 14 | $52.24 | |
| 80164 | <1% | 12 | $47.61 | |
| 82077 | <1% | 108 | $42.31 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 339 | $34.95 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 522 | $29.48 |
| 87075 | <1% | 13 | $28.82 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 140 | $24.36 |
| 82010 | <1% | 12 | $14.29 | |
| 73130 | <1% | 13 | $12.94 | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 153 | $11.43 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 15 | $11.18 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 384 | $10.37 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 114 | $9.20 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 440 | $8.02 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 261 | $7.16 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 519 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 154 | $0.00 |
| A6250 | Skin sealants, protectants, moisturizers, ointments, any type, any size | 0% | 81 | $0.00 |
| 93770 | 0% | 139 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 12 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 63 | $0.00 |
| A4311 | Insertion tray without drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | 0% | 61 | $0.00 |
| 82800 | 0% | 13 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 15 | $0.00 |
| 72100 | 0% | 14 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 456 | $0.00 |
| C1769 | Guide wire | 0% | 477 | $0.00 |
| 94761 | 0% | 423 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 43 | $0.00 |
| 82803 | 0% | 14 | $0.00 | |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 12 | $0.00 |
| 74022 | 0% | 12 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 27 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 59 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 15 | $0.00 |
| A4364 | Adhesive, liquid or equal, any type, per oz | 0% | 18 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGOESER, STEVEN (EXECUTIVE VICE PRESIDENT & COO)
| Provider | Location | Paid |
|---|---|---|
| Nebraska Methodist Hospital | Omaha, NE | $5.35M |
| Nebraska Methodist Hospital | Omaha, NE | $78.24 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.